Document is current
Any future updates will be listed below
-
Authors
Hamilton, Jennifer R. http://orcid.org/0000-0002-7136-1757
Chen, Evelyn http://orcid.org/0000-0003-1102-6997
Perez, Barbara S.
Sandoval Espinoza, Cindy R. http://orcid.org/0000-0003-2308-0413
Kang, Min Hyung
Trinidad, Marena
Ngo, Wayne
Doudna, Jennifer A. http://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (RM1HG009490, U01AI142817-02)
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (K99GM143461-01A1)
Jane Coffin Childs Memorial Fund for Medical Research
- License Information
-
More Information
Article History
Received: 25 August 2023
Accepted: 1 December 2023
First Online: 11 January 2024
Competing interests
: The Regents of the University of California have patents issued and/or pending for CRISPR technologies (on which J.A.D. is an inventor) and delivery technologies (on which J.A.D. and J.R.H. are co-inventors). J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. and J.R.H. are co-founders of Azalea Therapeutics. J.A.D. is a scientific advisory board member of Vertex, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Algen Biotechnologies, Felix Biosciences, The Column Group and Inari. J.A.D. is Chief Science Advisor to Sixth Street, a Director at Johnson & Johnson, Altos and Tempus, and has research projects sponsored by AppleTree Partners and Roche. All other authors have no competing interests.
